159 related articles for article (PubMed ID: 32515087)
1. Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up.
Schmitz R; Fitch ZW; Xu H; Ghali A; Mehta AK; Guasch A; Kirk AD
Am J Transplant; 2020 Dec; 20(12):3609-3619. PubMed ID: 32515087
[TBL] [Abstract][Full Text] [Related]
2. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
[TBL] [Abstract][Full Text] [Related]
3. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
[TBL] [Abstract][Full Text] [Related]
4. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
5. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
[TBL] [Abstract][Full Text] [Related]
6. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
[TBL] [Abstract][Full Text] [Related]
7. Increased CMV disease and "severe" BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.
Petrossian G; Ortiz J; Ortiz AC; Addonizio K; Hsiao A; James R; Koizumi N; Patel S; Plews R
Transpl Immunol; 2023 Aug; 79():101857. PubMed ID: 37201797
[TBL] [Abstract][Full Text] [Related]
8. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
Woodle ES; Kaufman DB; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Am J Transplant; 2020 Apr; 20(4):1039-1055. PubMed ID: 31680394
[TBL] [Abstract][Full Text] [Related]
9. IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection.
Xu H; Bendersky VA; Brennan TV; Espinosa JR; Kirk AD
Am J Transplant; 2018 Mar; 18(3):720-730. PubMed ID: 29136317
[TBL] [Abstract][Full Text] [Related]
10. Tailored use of belatacept in adolescent kidney transplantation.
Blew KH; Chua A; Foreman J; Gbadegesin R; Jackson A; Nagaraj S; Sadun R; Wigfall D; Kirk AD; Chambers ET
Am J Transplant; 2020 Mar; 20(3):884-888. PubMed ID: 31550421
[TBL] [Abstract][Full Text] [Related]
11. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
12. Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept.
Newell KA; Mehta AK; Larsen CP; Stock PG; Farris AB; Mehta SG; Ikle D; Armstrong B; Morrison Y; Bridges N; Robien M; Mannon RB
Am J Transplant; 2017 Oct; 17(10):2712-2719. PubMed ID: 28556519
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
16. Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial.
Mannon RB; Armstrong B; Stock PG; Mehta AK; Farris AB; Watson N; Morrison Y; Sarwal M; Sigdel T; Bridges N; Robien M; Newell KA; Larsen CP
Am J Transplant; 2020 Dec; 20(12):3599-3608. PubMed ID: 32558199
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
18. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
19. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
20. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
